Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy

Molecular Medicine Reports

Volumn 7, Issue 6, 2013, Pages 1904-1911

  Liu, Yong Ping ^a   Ling, Yang ^a   Qi, Qiu Feng ^a   Zhang, Ya Ping ^a   Zhang, Chang Song ^a   Zhu, Chang Tai ^a   Wang, Mei Hua ^a   Pan, Yao Dong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Gastric cancer; Genetic polymorphisms; Oxaliplatin; Toxicity; Treatment outcome

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN; XRCC1 PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DNA POLYMORPHISM; FEMALE; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN ANALYSIS; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; STOMACH CANCER; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84877258895     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1435     Document Type: Article

References (52)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Leung WK, Wu MS, Kakugawa Y, et al: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9: 279-287, 2008.
3. Macdonald JS: Treatment of localized gastric cancer. Semin Oncol 31: 566-573, 2004.
4. Carrato A, Gallego-Plazas J and Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol 32: S105-S108, 2005.
5. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL and Chaney SG: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54: 3500-3505, 1994.
6. Louvet C, André T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002.
7. De Vita F, Orditura M, Matano E, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92: 1644-1649, 2005.
8. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22: 658-663, 2004.
9. Cavanna L, Artioli F, Codignola C, et al: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 29: 371-375, 2006.
10. Wei Q, Frazier ML and Levin B: DNA repair: a double-edged sword. J Natl Cancer Inst 92: 440-441, 2000.
11. Reardon JT, Vaisman A, Chaney SG and Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59: 3968-3971, 1999.
12. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
13. Goode EL, Ulrich CM and Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1513-1530, 2002.
14. Wood RD, Mitchell M, Sgouros J and Lindahl T: Human DNA repair genes. Science 291: 1284-1289, 2001.
15. Frankmoelle WP, Medina JC, Shan B, Narbut MR and Beckmann H: Glutathione S-transferase metabolism of the antineoplastic pentafluorophenylsulfonamide in tissue culture and mice. Drug Metab Dispos 28: 951-958, 2000.
16. National Cancer Institute: NCI Common Toxicity Criteria. http://ctep.cancer.gov. Accessed October 1, 2004.
17. Salinas AE and Wong MG: Glutathione S-transferases -a review. Curr Med Chem 6: 279-309, 1999.
18. Gossage L and Madhusudan S: Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 11: 361-380, 2007.
19. De Silva IU, McHugh PJ, Clingen PH and Hartley JA: Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20: 7980-7990, 2000.
20. Weberpals J, Garbuio K, O'Brien A, et al: The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815, 2009.
21. Denlinger CS and Cohen SJ: Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol 8: 339-351, 2007.
22. Iqbal S, Stoehlmacher J and Lenz HJ: Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 22: 762-773, 2004.
23. Hofler H, Langer R, Ott K and Keller G: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Adv Exp Med Biol 587: 115-120, 2006.
24. Guichard S, Arnould S, Hennebelle I, Bugat R and Canal P: Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs 12: 741-751, 2001.
25. Chang PM, Tzeng CH, Chen PM, et al: ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 100: 278-283, 2009.
26. Kalikaki A, Kanaki M, Vassalou H, et al: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123, 2009.
27. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354, 2004.
28. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247-1254, 2007.
29. Yu JJ, Lee KB, Mu C, et al: Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16: 555-560, 2000.
30. Huang MY, Huang ML, Chen MJ, et al: Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21: 18-25, 2011.
31. Spitz MR, Wu X, Wang Y, et al: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61: 1354-1357, 2001.
32. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM and Abdel-Rahman SZ: Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 17: 897-905, 2007.
33. Lunn RM, Helzlsouer KJ, Parshad R, et al: XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551-555, 2000.
34. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S and Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658, 2001.
35. Zárate RN, Arias F, Bandres E, Cubedo E, Malumbres R and García-Foncillas J: Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J Gastroenterol 12: 6032-6036, 2006.
36. Tibaldi C, Giovannetti E, Vasile E, et al: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803, 2008.
37. Xing D, Tan W, Wei Q and Lin D: Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 38: 123-129, 2002.
38. Liu B, Wei J, Zou Z, et al: Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15: 1049-1053, 2007.
39. Vodicka P, Kumar R, Stetina R, et al: Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25: 757-763, 2004.
40. Vodicka P, Stetina R, Polakova V, et al: Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 28: 657-664, 2007.
41. Pacetti P, Giovannetti E, Mambrini A, et al: Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. Anticancer Res 29: 1835-1840, 2009.
42. Giachino DF, Ghio P, Regazzoni S, et al: Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13: 2876-2881, 2007.
43. Moreno V, Gemignani F, Landi S, et al: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101-2108, 2006.
44. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C and Choi S: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 13: 1379-1385, 2006.
45. de las Peñas R, Sanchez-Ronco M, Alberola V, et al: Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675, 2006.
46. Bewick MA, Conlon MS and Lafrenie RM: Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24: 5645-5651, 2006.
47. Yoon HH, Catalano PJ, Murphy KM, et al: Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer 11: 176, 2011.
48. Cheng XD, Lu WG, Ye F, Wan XY and Xie X: The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res 28: 91, 2009.
49. Huang ZH, Hua D and Du X: Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64: 1001-1007, 2009.
50. Goekkurt E, Al-Batran SE, Hartmann JT, et al: Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27: 2863-2873, 2009.
51. Kweekel DM, Koopman M, Antonini NF, et al: GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 99: 1316-1321, 2008.
52. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002.